Filing Details
- Accession Number:
- 0000899243-22-016433
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-03 19:29:27
- Reporting Period:
- 2022-04-30
- Accepted Time:
- 2022-05-03 19:29:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1596946 | Quotient Ltd | QTNT | In Vitro & In Vivo Diagnostic Substances (2835) | 264719797 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1823186 | Isabelle Buckle | C/O Quotient Limited, Business Park Terre Bonne, Route De Crassier 13 Eysins V8 1262 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Disposition | 2022-05-02 | 2,143 | $0.00 | 31,234 | No | 4 | S | Direct | |
Ordinary Shares | Acquisiton | 2022-04-30 | 6,917 | $0.00 | 33,377 | No | 4 | M | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | M | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Restricted Stock Units | Disposition | 2022-04-30 | 6,917 | $0.00 | 6,917 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
13,834 | No | 4 | M | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Ordinary Shares | Ordinary Share Option (Right to Buy) | $4.81 | 2030-09-01 | 20,790 | 20,790 | Direct | |
Ordinary Shares | Ordinary Share Option (Right to Buy) | $4.81 | 2030-09-01 | 2,171 | 2,171 | Direct | |
Ordinary Shares | Ordinary Share Option (Right to Buy) | $4.55 | 2030-10-31 | 13,611 | 13,611 | Direct | |
Ordinary Shares | Ordinary Share Option (Right to Buy) | $2.53 | 2031-10-31 | 24,040 | 24,040 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2030-09-01 | 20,790 | 20,790 | Direct |
2030-09-01 | 2,171 | 2,171 | Direct |
2030-10-31 | 13,611 | 13,611 | Direct |
2031-10-31 | 24,040 | 24,040 | Direct |
Footnotes
- Restricted Stock Units convert into ordinary shares on a one-for-one basis.
- 6,930 options vested on September 1, 2021 and remain exercisable, and the remaining 13,860 options will vest in two equal installments on September 1, 2022 and September 2, 2023.
- 724 options vested on October 31, 2021 and remain exercisable, and the remaining 723 options will vest on October 31, 2022.
- All 13,611 options have vested and remain exercisable.
- On October 31, 2021, the Reporting Person was granted 27,668 restricted stock units, of which 13,834 have vested and have converted into ordinary shares. The remaining 13,834 restricted stock units will vest in two equal installments on July 31, 2022 and October 31, 2022.
- The options vest and become exercisable on October 31, 2022.
- The sale reported on this Form 4 is a sale to cover taxes arising from the vesting and settlement of RSU awards. This sale is mandated by the Reporting Person's election to fund such taxes by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer.